Avelumab and Merkel Cell Carcinoma: Examining the Evidence on Risk and Causation

From General Health Literacy to Specific Exposure Concerns

For decades, general health and science communication has served as the foundation for public understanding of medical risks and therapeutic options. This legacy context has traditionally emphasized broad wellness principles, disease prevention, and the importance of evidence-based decision-making. Within this framework, audiences have been educated about the balance between treatment benefits and potential adverse effects, often framed in terms of lifestyle factors or population-level statistics. As scientific inquiry has advanced, however, the focus has increasingly shifted toward specific exposures and their nuanced relationships with health outcomes. In the domain of mass production, where large-scale manufacturing processes involve the use of pharmaceutical agents, a more targeted question emerges: what does the evidence reveal about the association between exposure to avelumab—a therapeutic monoclonal antibody—and the risk of developing Merkel cell carcinoma? This pivot from general health literacy to occupational exposure concern requires careful examination of available studies, without venturing into mechanistic speculation. The transition thus moves from a broad educational heritage to a precise inquiry into whether avelumab exposure, particularly in production settings, may be linked to increased cancer risk, as reported in epidemiological and clinical research.

Understanding Avelumab and Its Role in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the human Merkel cell polyomavirus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab and pembrolizumab, offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). For patients who are refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Evidence on Avelumab and Merkel Cell Carcinoma Risk: Causation vs. Treatment

Regarding causation-related considerations, avelumab is approved specifically for the treatment of metastatic MCC, meaning that its use is indicated in patients already diagnosed with this malignancy. The risk narrative here does not involve avelumab causing MCC de novo; rather, the drug is a therapeutic agent for an existing condition. The evidence does not suggest that avelumab induces or increases the risk of developing MCC. Instead, the risk concerns the adequacy of warnings about avelumab's efficacy and safety in treating MCC, including the potential for lack of response or progression despite treatment. The timeline between exposure to avelumab and documented harm is relevant to patients who do not respond or who experience immune-related adverse events. In the JAVELIN Merkel 200 trial, responses were observed in approximately one-third of patients, indicating that a majority did not achieve an objective response (https://pubmed.ncbi.nlm.nih.gov/29799096/). The evidence shows that about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy, and that avelumab-refractory patients may have limited options (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/33439294/). The development of immune-related adverse events can occur during treatment, and mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines may contribute to lack of response or adverse events (https://pubmed.ncbi.nlm.nih.gov/34445385/). In summary, the evidence indicates that avelumab is an approved therapy for metastatic MCC with demonstrated efficacy in a subset of patients, but a significant proportion do not respond or progress. The risk for affected patients primarily involves the possibility of treatment failure or immune-related adverse events, rather than avelumab causing MCC. Adequacy of warnings should address these outcomes, including the lack of response in approximately 50% of patients and the potential for progression despite treatment. The timeline from exposure to harm can vary, with responses or adverse events typically occurring during the course of therapy.

Treatment Options for Avelumab-Refractory Merkel Cell Carcinoma

Studies have investigated the use of combined ipilimumab plus nivolumab in avelumab-refractory MCC. In a retrospective study at three academic sites in Germany, three out of five patients with metastatic MCC refractory to avelumab responded to combined ipilimumab plus nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported on the use of ipilimumab plus nivolumab in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study examined ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC, noting that despite advances in systemic therapy, about 50% of patients treated with immune checkpoint inhibitors progress (https://pubmed.ncbi.nlm.nih.gov/35877101/). These findings highlight the ongoing need for effective therapies in patients who do not respond to avelumab.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is a treatment for Merkel cell carcinoma (MCC), not a cause. It is approved for metastatic MCC and works by targeting PD-L1. The evidence does not suggest that avelumab induces or increases the risk of developing MCC. Instead, the risk concerns treatment failure or immune-related adverse events in patients already diagnosed with MCC.

What is the risk of not responding to avelumab treatment?

Approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors like avelumab do not respond or progress on therapy. For those who are refractory, treatment options are limited, though combination therapies such as ipilimumab plus nivolumab have shown some efficacy in small studies.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.